Trial Profile
A Phase 2 Double-blind Placebo-controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing S. Aureus Colonization
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 May 2021
Price :
$35
*
At a glance
- Drugs NDV 3 (Primary)
- Indications Staphylococcal infections
- Focus Therapeutic Use
- Sponsors NovaDigm Therapeutics
- 04 May 2021 Primary endpoint (Prevent acquisition of incident Staphylococcus aureus nasal colonization) has not been met as per results published in the Vaccine
- 04 May 2021 Results published in the Vaccine
- 28 Jan 2020 Status changed from active, no longer recruiting to completed.